A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Objectives: Primary Objectives: * To assess the clinical activity and safety of luspatercept in patients with transfusion independent lower risk MDS * To assess the clinical activity and safety of luspatercept in patients with transfusion dependent lower risk MDS * To study the effects on hematopoeisis of luspatercept in patients treated on this study Secondary Objectives: * To assess the duration of response of patients with treated with luspatercept in this study * To assess the overall survival and time to transformation of patients with treated with luspatercept in this study * To assess transfusion free survival period in patients that were transfusion independent treated with luspatercept in this study * To measure trends in neutrophil and platelet counts in patients treated in this study